Septerna, Inc. SEPN
Regular-session close
After hours · Nov 19, 4:27 PM ET
- YTD
- +40.60%
- 1 year
- +69.70%
5D -2.84 (-6.76%)
- Market cap
- 1.86B
- Revenue (ttm)
- 96.27M
- Profit margin
- -61.29%
- EPS (ttm)
- -1.29
- Shares out
- 47.55M
- Forward P/E
- -25.81
- YTD return
- +40.60%
- 1-year return
- +69.70%
- 50-day average
- 40.64
- 200-day average
- 33.36
- Volume
- 209.02K
- Avg volume
- 386.09K
- Open
- 39.96
- Previous close
- 39.45
- Day's range
- 38.77 – 40.20
- 52-week range
- 23.09 – 52.34
- Beta
- 2.20
- Analysts
- Strong Buy
- Price target
- 59.56 (+51.9%)
- Earnings date
- Mar 8, 2027
Key statistics
- Enterprise value
- 1.42B
- Price / sales
- 19.36
- Price / book
- 4.34
- Revenue growth
- -12.20%
- Free cash flow
- -7.81M
- Total cash
- 478.60M
- Total debt
- 21.99M
- Return on equity
- -14.45%
- Short % of float
- 13.33%
Fundamental scorecard
5 of 25 checks passed on SEPN’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 51.00
- Target (mean)
- 59.56
- Target (high)
- 65.00
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 8, 2027
Expected Mar 8, 2027. Consensus EPS estimate -0.3175.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 8, 2027 | Dec 30, 2026 | -0.57 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.415 | -0.57 | -0.15 | -37.35% |
| Aug 10, 2026 | Jun 30, 2026 | -0.426 | -0.29 | +0.14 | +31.92% |
| May 12, 2026 | Mar 31, 2026 | -0.51 | -0.19 | +0.32 | +62.75% |
| Mar 9, 2026 | Dec 31, 2025 | -0.23 | -0.24 | -0.01 | -4.35% |
| Nov 10, 2025 | Sep 30, 2025 | 0.19 | -0.09 | -0.28 | -147.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Stifel | main | Buy | Buy |
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Nov 4, 2026 | Wells Fargo | main | Overweight | Overweight |
| Aug 19, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 13, 2026 | Jones Trading | main | Buy | Buy |
| Aug 12, 2026 | Wells Fargo | main | Overweight | Overweight |
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- septerna.com
News
JP Morgan Maintains Overweight on Septerna, Raises Price Target to $51
Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
Septerna: The SEP-479 Readout Could Unlock Further Upside Stifel Maintains Buy on Septerna, Raises Price Target to $60
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates Septerna Q3 EPS $(0.57) Misses $(0.45) Estimate, Sales $18.881M Miss $20.780M Estimate
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results Guggenheim Maintains Buy on Septerna, Raises Price Target to $65
Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $61
Your note
Sign in to keep a note on SEPN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHATT ELIZABETH | President | Conversion of Exercise of derivative security | Oct 14, 2026 | 174,209 |
| EZEKOWITZ ALAN | Director | Sale | Nov 10, 2026 | 35,600 |
| FINER JEFFREY | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 11, 2026 | 833,909 |
| KLEIN UWE | Officer | Conversion of Exercise of derivative security | Aug 17, 2025 | 127,533 |
| LABRUCHERIE GILBERT M JR | Chief Financial Officer | Sale | Nov 15, 2026 | 0 |
| LONG DANIEL D | Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 96,412 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trv Gp V, LLC | 12.76% | 6,068,391 | 237.88M | Sep 29, 2026 |
| RA Capital Management, L.P. | 11.57% | 5,502,858 | 215.71M | Sep 29, 2026 |
| Driehaus Capital Management, LLC | 8.99% | 4,273,431 | 167.52M | Sep 29, 2026 |
| Trv Gp VI, LLC | 8.86% | 4,211,659 | 165.10M | Sep 29, 2026 |
| Samsara BioCapital, LLC | 6.45% | 3,066,453 | 120.20M | Sep 29, 2026 |
| Goldman Sachs Group Inc | 6.35% | 3,018,431 | 118.32M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.95% | 927,665 | 36.36M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.91% | 907,722 | 35.58M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.21% | 574,604 | 22.52M | Sep 29, 2026 |
| Driehaus Mutual Funds-Driehaus Small Cap Growth Fund | 0.88% | 417,859 | 16.38M | Jun 29, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund | 0.71% | 338,579 | 13.27M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.55% | 261,547 | 10.25M | Jun 29, 2026 |
